Latest NPS Pharmaceuticals (NPSP) Headlines
Earnings Look Back: NPS Pharmaceuticals Is Down 12.6% Since Reporting Quarterly Results 2 Weeks Ago (NPSP)
Comtex SmarTrend(R) - Mon Mar 10, 7:48AM CDT
Two weeks ago on February 18th, 2014 NPS Pharmaceuticals (NASDAQ:NPSP) reported earnings and analysts, on average, expected earnings of $0.03 on sales of $45.2 million. The company actually reported EPS of $0.07 on sales of $54.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $9.3 million. Shares of NPS Pharmaceuticals have slipped from $37.95 to $33.18, representing a loss of 12.6%, since the company reported earnings 20 days ago.
Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals
PR Newswire - Wed Mar 05, 12:08PM CST
Editor Note: For more information about this release, please scroll to bottom.
NPS Pharmaceuticals Has Returned 30.2% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Wed Mar 05, 11:08AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on December 19th, 2013 at $27.04. In approximately 3 months, NPS Pharmaceuticals has returned 30.24% as of today's recent price of $35.21.
NPS Pharmaceuticals Joins Participants from around the World in Observing Rare Disease Day
Business Wire - Fri Feb 28, 7:30AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today joins patient organizations, healthcare professionals, researchers, public health authorities and the biopharmaceutical industry in recognizing Rare Disease Day. As a "Friend of Rare Disease Day," NPS strives to increase recognition of rare diseases and educate the public about their global impact on society. Internationally, the observance is led by the European Organisation for Rare Diseases (EURORDIS) and in the US by the National Organization for Rare Disorders (NORD).
NPS Pharmaceuticals to Present at Barclays Global Healthcare Conference
Business Wire - Wed Feb 26, 3:10PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 11, 2014 at 9:00 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com/calendar.
Look for Shares of NPS Pharmaceuticals to Potentially Rebound after Yesterday's 4.22% Sell Off
Comtex SmarTrend(R) - Wed Feb 19, 5:39PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $36.00 to a high of $37.94. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $36.94 on volume of 2.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why NPS Pharmaceuticals, Inc. Shares Slipped
Brian Pacampara, The Motley Fool - Motley Fool - Wed Feb 19, 1:21PM CST
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
37.0% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Wed Feb 19, 9:12AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on December 19th, 2013 at $27.04. In approximately 2 months, NPS Pharmaceuticals has returned 36.97% as of today's recent price of $37.03.
NPS Pharma Swings to Earnings on Strong Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:10AM CST
NPS Pharma's fourth quarter earnings were ahead of the Zacks Consensus Estimate.
Downgrade Alert for NPS Pharmaceuticals (NPSP)
Comtex SmarTrend(R) - Wed Feb 19, 6:57AM CST
NPS Pharmaceuticals (NASDAQ:NPSP) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $37.95 on volume of 2.4 million shares, above average daily volume of 1.9 million. In the past 52 weeks, NPS Pharmaceuticals share prices have been bracketed by a low of $7.35 and a high of $38.74 and closed yesterday at $37.95, 416% above that low price. Over the past week, the 200-day moving average (MA) has gone up 2.5% while the 50-day MA has advanced 3.7%.
NPS Pharmaceuticals' Q4 Revenue Doubles as It Reverses a Year-Ago Loss
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 5:01PM CST
NPS Pharmaceuticals continued to live up its too hot to handle reputation in the after-hours this evening after the biopharmaceutical company reported robust sales and bottom-line growth with its fourth-quarter results . For the quarter, NPS'...
NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
Business Wire - Tue Feb 18, 3:30PM CST
--- Global Short Bowel Syndrome franchise expected to grow by more than 250% in 2014 --
Will NPS Pharma (NPSP) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 1:40PM CST
NPS Pharmaceuticals has an earnings ESP of 0.00% with a Zacks Rank #3 (Hold)
NPS Pharma Finds Big Success In Tiny Markets
at Investor's Business Daily - Thu Feb 13, 5:15PM CST
A lot of drug companies outsource parts of their operations -- manufacturing, for instance, or running clinical trials. Back in 2007, Francois Nader had a more radical idea: What if you outsource everything? Nader was an executive at NPS...
SmarTrend Watching for Potential Pullback in Shares of NPS Pharmaceuticals After 4.28% Gain
Comtex SmarTrend(R) - Wed Feb 12, 5:48PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $36.55 to a high of $38.74. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $36.76 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Critical Alerts For Apple, NPS Pharmaceuticals, General Motors, U.S. Steel, and Dollar Tree Released By InvestorsObserver
PR Newswire - Tue Feb 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, NPSP, GM, X, and DLTR.
Earnings Look Back: NPS Pharmaceuticals Is Down 12.6% Since Reporting Quarterly Results 2 Weeks Ago (NPSP)
Comtex SmarTrend(R) - Mon Mar 10, 7:48AM CDT
Two weeks ago on February 18th, 2014 NPS Pharmaceuticals (NASDAQ:NPSP) reported earnings and analysts, on average, expected earnings of $0.03 on sales of $45.2 million. The company actually reported EPS of $0.07 on sales of $54.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $9.3 million. Shares of NPS Pharmaceuticals have slipped from $37.95 to $33.18, representing a loss of 12.6%, since the company reported earnings 20 days ago.
Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals
PR Newswire - Wed Mar 05, 12:08PM CST
Editor Note: For more information about this release, please scroll to bottom.
NPS Pharmaceuticals Has Returned 30.2% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Wed Mar 05, 11:08AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on December 19th, 2013 at $27.04. In approximately 3 months, NPS Pharmaceuticals has returned 30.24% as of today's recent price of $35.21.
NPS Pharmaceuticals Joins Participants from around the World in Observing Rare Disease Day
Business Wire - Fri Feb 28, 7:30AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today joins patient organizations, healthcare professionals, researchers, public health authorities and the biopharmaceutical industry in recognizing Rare Disease Day. As a "Friend of Rare Disease Day," NPS strives to increase recognition of rare diseases and educate the public about their global impact on society. Internationally, the observance is led by the European Organisation for Rare Diseases (EURORDIS) and in the US by the National Organization for Rare Disorders (NORD).
NPS Pharmaceuticals to Present at Barclays Global Healthcare Conference
Business Wire - Wed Feb 26, 3:10PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 11, 2014 at 9:00 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com/calendar.
Look for Shares of NPS Pharmaceuticals to Potentially Rebound after Yesterday's 4.22% Sell Off
Comtex SmarTrend(R) - Wed Feb 19, 5:39PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $36.00 to a high of $37.94. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $36.94 on volume of 2.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why NPS Pharmaceuticals, Inc. Shares Slipped
Brian Pacampara, The Motley Fool - Motley Fool - Wed Feb 19, 1:21PM CST
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
37.0% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Wed Feb 19, 9:12AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on December 19th, 2013 at $27.04. In approximately 2 months, NPS Pharmaceuticals has returned 36.97% as of today's recent price of $37.03.
NPS Pharma Swings to Earnings on Strong Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:10AM CST
NPS Pharma's fourth quarter earnings were ahead of the Zacks Consensus Estimate.
Downgrade Alert for NPS Pharmaceuticals (NPSP)
Comtex SmarTrend(R) - Wed Feb 19, 6:57AM CST
NPS Pharmaceuticals (NASDAQ:NPSP) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $37.95 on volume of 2.4 million shares, above average daily volume of 1.9 million. In the past 52 weeks, NPS Pharmaceuticals share prices have been bracketed by a low of $7.35 and a high of $38.74 and closed yesterday at $37.95, 416% above that low price. Over the past week, the 200-day moving average (MA) has gone up 2.5% while the 50-day MA has advanced 3.7%.
NPS Pharmaceuticals' Q4 Revenue Doubles as It Reverses a Year-Ago Loss
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 5:01PM CST
NPS Pharmaceuticals continued to live up its too hot to handle reputation in the after-hours this evening after the biopharmaceutical company reported robust sales and bottom-line growth with its fourth-quarter results . For the quarter, NPS'...
NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
Business Wire - Tue Feb 18, 3:30PM CST
--- Global Short Bowel Syndrome franchise expected to grow by more than 250% in 2014 --
Will NPS Pharma (NPSP) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 1:40PM CST
NPS Pharmaceuticals has an earnings ESP of 0.00% with a Zacks Rank #3 (Hold)
NPS Pharma Finds Big Success In Tiny Markets
at Investor's Business Daily - Thu Feb 13, 5:15PM CST
A lot of drug companies outsource parts of their operations -- manufacturing, for instance, or running clinical trials. Back in 2007, Francois Nader had a more radical idea: What if you outsource everything? Nader was an executive at NPS...
SmarTrend Watching for Potential Pullback in Shares of NPS Pharmaceuticals After 4.28% Gain
Comtex SmarTrend(R) - Wed Feb 12, 5:48PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $36.55 to a high of $38.74. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $36.76 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Critical Alerts For Apple, NPS Pharmaceuticals, General Motors, U.S. Steel, and Dollar Tree Released By InvestorsObserver
PR Newswire - Tue Feb 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, NPSP, GM, X, and DLTR.
